News: Statins (cholesterol-lowering drugs) appear to help prevent cancer-causing chronic inflammation. This #NIAMSfunded study is available in #OpenAccess via Nature Communications: https://lnkd.in/gtfnWAJy #MouseModels
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Services
Bethesda, Maryland 2,101 followers
About us
The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.
- Website
- http://www.niams.nih.gov/
External link for National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- Bethesda, Maryland
- Type
- Government Agency
Locations
- Primary
31 Center Drive
Bethesda, Maryland 20892, US
Employees at National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Updates
-
Many men experience conditions and diseases of the bones, joints, muscles, and skin. #NationalMensHealthMonth is an opportunity to remind men and boys about health problems and encourage them to seek regular medical advice and early treatment for disease and injury.
-
Back pain news: Researchers at The Ohio State University developed a novel gene therapy that was shown to not only relieve symptomatic pain – but also restore damaged discs – in a mouse model of back pain. Read the #OpenAccess study via Biomaterials: https://lnkd.in/euspnEBN #NIAMSfunded
-
Last year, a #NIAMSfunded study identified subtypes of inflammation in people with rheumatoid arthritis — an advancement could lead to more tailored RA treatments. Learn the details behind the science: https://go.nih.gov/CjF0O6F #ArthritisAwarenessMonth
-
Congratulations to Dr. John O’Shea, NIAMS Scientific Director of Intramural Research, for being formally inducted into the National Academy of Sciences! This designation – considered one of the highest honors that a scientist can achieve – recognizes distinguished and continuing achievements in original research.
-
On Friday, May 31, join NIAMS and the DC Lupus Consortium for the 30th anniversary of Lupus Clinical Research! This in-person event at the NIH Clinical Center will highlight the outstanding progress in lupus clinical research made by NIH over the last 30 years, featuring testimonials from research participants, updates on current lupus research activities at NIAMS, and discussions on the future direction of research at the NIH. The event seeks to build on the success of DC Lupus Consortium — a platform to collaborate between NIH scientists, physicians outside the NIH, and patient advocacy groups interested in Lupus Clinical Research. Stakeholders that have a vested interest in lupus clinical research such as patients, NIH scientists, researchers, patient advocacy groups, and physicians both within and outside of NIH are welcome to join this consortium. Learn more and register: https://lnkd.in/dE_ypThr
-
NIAMS Lupus Clinical Trials Unit chief Dr. Sarfaraz Hasni and members of his team joined Maryland's Montgomery County Government Council yesterday for the county’s #LupusAwarenessMonth proclamation. Dr. Hasni made public remarks expressing gratitude to the #LupusWarriors for making clinical trials possible and stressed the importance of community engagement with underrepresented populations.
-
News: Scientists at the NIH have discovered that the presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors. The condition, known as BAP1 tumor predisposition syndrome (BAP1 TPDS), is caused by mutations in the BAP1 gene, which normally acts as a tumor suppressor, among other functions. The nail abnormality – which typically affects only one nail – causes a colored band along the length of the nail, along with thickening of the nail. However, among study participants aged 30 and older, 88 percent had the abnormality affect multiple nails. Researchers suggest that nail screening may be particularly valuable in a patient with a personal or family history of melanoma or other potential BAP1-associated malignancy: https://go.nih.gov/RUwDLPQ
-
Arthritis affects over 50 million people in the U.S. – and we are dedicated to supporting research into its causes, prevention, and treatment. Watch this video to see #ArthritisExplained. #ArthritisAwarenessMonth